Clincosm LogoSign in Get a demo

Macular Thickness and Visual Acuity in Diabetic Hypertensive Patients

Sponsor
Sohag University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05209971
Collaborator
(none)
100
Enrollment
11
Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

In this study, measurements of central macular thickness using optical coherence tomography along with examination of visual acuity by Snellen's chart in diabetic hypertensive patients will be done .

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    correlate relationship between optical coherence tomography changes and visual acuity in patients with type 2 diabetes and hypertension

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    100 participants
    Observational Model:
    Case-Only
    Time Perspective:
    Retrospective
    Official Title:
    Macular Thickness and Visual Acuity in Diabetic Hypertensive Patients in Sohag City
    Anticipated Study Start Date :
    Jan 1, 2022
    Anticipated Primary Completion Date :
    Jun 1, 2022
    Anticipated Study Completion Date :
    Dec 1, 2022

    Arms and Interventions

    Arm Intervention/Treatment
    macular thickness and visual acuity

    optical coherence tomography

    Outcome Measures

    Primary Outcome Measures

    1. macular thickness in diabetic hypertensive patients [June 2022]

      measurement of central macular thickness by optical coherence tomography

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Type 2 diabetic patients with hypertension .
    Exclusion Criteria:

    • Patients with type 1 diabetes mellitus .

    • Ocular disease ( such as high myopia , glaucoma ) .

    • Patients with opacities in the media ( corneal opacities , dense cataract , vitreous hemorrhage ) .

    • Systemic medication (Tamoxifen , Chloroquine , Canthaxanthine ) to avoid its effect on macular thickness .

    • Central visual field defect that prevents fixation on OCT .

    • Intraocular inflammation such as anterior or posterior uveitis .

    • Refractive error greater than 6 diopter .

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Sohag University

    Investigators

    • Principal Investigator: Raghda Abdelraheem, doctor, faculty of medicine

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Raghda Abdelraheem Abdellah, principal investigator, Sohag University
    ClinicalTrials.gov Identifier:
    NCT05209971
    Other Study ID Numbers:
    • Soh-Med-22-01-05
    First Posted:
    Jan 27, 2022
    Last Update Posted:
    Jan 27, 2022
    Last Verified:
    Jan 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Raghda Abdelraheem Abdellah, principal investigator, Sohag University
    Macular thickness and visual acuity
    Additional relevant MeSH terms:
    Macular Edema

    Study Results

    No Results Posted as of Jan 27, 2022